News
-
-
-
PRESS RELEASE
Affluent Medical annonce la mise à disposition d'un prospectus au titre de l'admission aux négociations de 6.190.831 actions émises dans le cadre d'une augmentation de capital avec suppression du DPS.
Affluent Medical annonce l'admission aux négociations de 6.190.831 actions nouvelles suite à une augmentation de capital avec suppression du DPS -
PRESS RELEASE
Affluent Medical announces the availability of a prospectus for the admission to trading of 6,190,831 shares issued as part of a capital increase without preferential subscription rights.
Affluent Medical announces availability of a prospectus for trading of 6,190,831 shares in connection with a capital increase without preferential subscription rights. The AMF-approved Prospectus includes details of the Capital Increase -
PRESS RELEASE
Affluent Medical announces the availability of a prospectus for the admission to trading of 6,190,831 shares issued as part of a capital increase without preferential subscription rights in favour of
Affluent Medical announces a capital increase without preferential subscription rights involving the trading of 6,190,831 shares. Edwards Lifesciences becomes a 9.21% shareholder after subscribing for €5 million. Risk factors are highlighted in the available prospectus -
-
-
-
PRESS RELEASE
Evolva Holding SA: Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules; IFRS financial statements for 2023 and half-year 2024 to be publish
Evolva Holding SA receives temporary exemption from listing conditions to publish IFRS financial statements by October 31, 2024 after shareholder resolution. Ad hoc announcement pursuant to Art. 53 LR -
